Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
May 09, 2024 16:25 ET
|
Genelux Corporation
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
The Benchmark Company Announces Upcoming Healthcare House Call VIRTUAL One-on-One Investor Conference
May 06, 2024 10:21 ET
|
The Benchmark Company
NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- The Benchmark Company is pleased to announce our upcoming Healthcare House Call VIRTUAL One-on-One Investor Conference happening on Tuesday &...
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 01, 2024 07:00 ET
|
Genelux Corporation
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Nanomedicine Global Market to Observe Stupendous Growth at a CAGR of ~11% by 2028 | DelveInsight
January 09, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Nanomedicine Global Market to Observe Stupendous Growth at a CAGR of ~11% by 2028 | DelveInsight Nanomedicine is experiencing heightened demand,...
Biopharmaceuticals Global Market is Expected to Surpass 700 Billion Mark by 2028, Assesses DelveInsight
January 02, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Biopharmaceuticals Global Market is Expected to Surpass 700 Billion Mark by 2028, Assesses DelveInsight The demand for biopharmaceuticals is...
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
November 27, 2023 07:00 ET
|
Genelux Corporation
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
Intratumoral Cancer Therapies Market to Observe Stupendous Growth During the Forecast Period (2023–2032), Assesses DelveInsight | Key Players - Nanobiotix, Sirnaomics, Apexigen, Replimune, Merck, OncoSec, DNAtrix, Treovir Istari
November 15, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Intratumoral Cancer Therapies Market to Observe Stupendous Growth During the Forecast Period (2023–2032), Assesses DelveInsight | Key Players -...
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
November 14, 2023 17:50 ET
|
Genelux Corporation
- Expanded executive team as Lourie Zak appointed Chief Financial Officer - - Extended clinical focus on systemic administration in small cell lung cancer - - $29.9 million in cash and equivalents...
Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 14, 2023 07:00 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the...
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
September 07, 2023 16:01 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President,...